Seattle Genetics, Inc. Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination With Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma (DLBCL)

Published: Aug 15, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The study is intended to evaluate the complete remission rate and safety of the A+RCHOP regimen. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for the treatment of DLBCL.

Help employers find you! Check out all the jobs and post your resume.

Back to news